Breast Cancer
-
Forward Look
CDK4/6 Inhibitors in Early-stage Breast CancerA mainstay of treatment for metastatic breast cancer, CDK4/6 inhibitors are moving into early-stage treatment.
by Darcy Lewis
-
Moving the Needle on Metastatic Breast CancerMetastatic breast cancer remains incurable, but researchers’ understanding of the molecular features of the disease is leading to additional treatments.
by Erin O’Donnell
-
Patient Advocates as Research PartnersSpeakers at SABCS discuss how people who have lived with breast cancer can be valuable partners in research.
by Eric Fitzsimmons
-
Understanding Side Effects and the Patient ExperienceResearchers focus on assessing quality of life and toxicity risks in people with breast cancer.
by Thomas Celona
-
Addressing Social Determinants of HealthSpeakers at SABCS discuss measuring and meeting social factors that affect the health and outcomes of breast cancer patients.
by Kevin McLaughlin
-
Exercise Benefits in Metastatic Breast CancerStudy finds supervised physical activity can help improve quality of life and reduce fatigue among people with metastatic breast cancer.
by Thomas Celona
-
Is Chemo-free Treatment Coming for HER2-positive Breast Cancer?Evidence grows that some people with HER2-positive breast cancer may do well on HER2-targeted therapy alone.
by Myles Starr
-
Germline Genetic Testing Lags Behind GuidelinesLow rates of germline genetic testing in cancer patients means information that could affect treatment isn’t available.
by Jon Kelvey
-
Making Treatment DecisionsIt’s not always clear what to do when cancer progresses. Abigail Johnston shares how she has approached treatment decisions since her metastatic breast cancer diagnosis in 2017.
by Abigail M. Johnston
-
Forward Look
The Chemotherapy ChoiceAdding an anthracycline to taxane chemotherapy regimens can reduce recurrence risk in early-stage breast cancer, but side effects also factor into treatment decisions.
by Kris Conner
